New frontiers of ophthalmology - Part II

Article

In the second of a two-part article Drs Lombardi and Belilli present the results of a patient suffering with a wet maculopathy affecting both eyes.

In October 2005, further to an examination, she was diagnosed with maculopathy of the left eye and subsequently underwent eight sessions of photodynamic therapy, with the tragic outcome of the vision in her left eye being reduced from 8/10 to finger count at 10 cm.

When Professor Lombardi's team first saw her back on 5th March, 2007 they observed the following clinical picture:

Treatment with autologous stem cells was performed on April 25th 2008. The patient was administered approx. 4 ml of stem cells in one deep retrobulbar injection.

Outcome

This was followed by a visus improvement of the right eye with a -1.5 -0.5 correction (110°)→ 10/10 and of the left eye with a -1.5 -1.5 correction (170°)→ 1/50 wide.

The Macula-Threshold test is particularly important as regards photosensibility indexes directly related to the "bio-energetic index" of retinal photo-receptors, since it shows two things:

2. when the value was below 28-30, at the level of the visual field, the photo-receptor involved was probably 'Bio-energised' through 'Bio-resonance,' thereby increasing its absolute sensibility levels.

Conclusions

"We are putting all our efforts in this new frontier with pride and satisfaction, as wehave done with other breakthroughs in ophthalmology in the past and we are now starting to reap the fruit of this work.

"Day after day we have been perfecting both the preparatory stage and the stem cell treatment itself. So, we will return to this issue with new articles and updates on ongoing treatments and results."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Related Content
© 2025 MJH Life Sciences

All rights reserved.